• Home
  • » 
  • Reports
  • » 
  • SARM1 Inhibitors Market by Target Indica...

SARM1 Inhibitors Market

SARM1 Inhibitors Market by Target Indications (Multiple Sclerosis, Peripheral, Central and Ocular Nervous System Disorders, Peripheral Neuropathies, Glaucoma and Amyotrophic Lateral Sclerosis), Type of Molecules (Small Molecules and Biologics), Drug Developers, Drug Candidates and Key Geographies (North America and Europe): Industry Trends and Global Forecasts, 2022-2040

  • Lowest Price Guaranteed From USD 5,899

  • Published
    November 2022

  • Slides
    90

  • View Count
    2016

  • Buy Now

Example Insights

SARM1-Targeting-Therapeutics-Market-Context-thumb SARM1-Targeting-Therapeutics-Market-Under-Development-thumb SARM1-Targeting-Therapeutics-Market-Pipeline-Review-thumb
SARM1-Targeting-Therapeutics-Market-Competitiveness-Analysis-thumb SARM1-Targeting-Therapeutics-Market-Publication-Analysis-thumb SARM1-Targeting-Therapeutics-Market-Grant-Analysis-thumb
SARM1-Targeting-Therapeutics-Market-Patent-Analysis-thumb SARM1-Targeting-Therapeutics-Market-Market-Opportunity-thumb SARM1-Targeting-Therapeutics-Market-Drug-Developer-thumb

Report Description

Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide. Across the globe, over 6.5 million neurological disorder related deaths are reported annually. Further, according to a report published by the United Nations (UN), close to 1 billion people, globally, suffer from various types of neurological disorders. The growing number of patients suffering from neurodegenerative disorders has imposed a huge burden, in terms of finances as well as resources, on the overall healthcare system. In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone. Given the fact that majority of the current treatment options have proven to be inadequate, especially for axonal degeneration associated neurological disorders, there is a high demand for highly effective therapeutics targeting neurological disorders. Interestingly, Sterile Alpha and toll / Interleukin-1 Receptor Motif-Containing 1 (SARM1), an NADase enzyme, has been found to play a critical role in inducing axonal degeneration, which is a central pathological feature in various neurodegenerative disorders.

Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis  across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various private and public organizations. Additionally, several patents related to SARM1 inhibitors have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 inhibitors market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The ‘SARM1 Inhibitors Therapeutics Market by Target Indications (Multiple Sclerosis, Peripheral, Central and Ocular Nervous System Disorders, Peripheral Neuropathies, Glaucoma and Amyotrophic Lateral Sclerosis), Type of Molecule (Small Molecules and Biologics), Drug Developers, Drug Candidates and Key Geographical Regions (North America and Europe): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:

  • A brief introduction to SARM1 inhibitors therapeutics, featuring information on role of SARM1 pathway in neurodegenerative disorders, mechanism of action of SARM1, along with mechanism of SARM1 pathway inhibition. This chapter further features details related to the recent advancements and future prospects in this domain.
  • A detailed overview of the current market landscape of SARM1 inhibitors therapeutics that are currently being researched in pre-clinical studies, featuring an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical and discovery), type of molecule (small molecules and biologics), target indication (unspecified neurological disorders, amyotrophic lateral sclerosis, multiple sclerosis, peripheral neuropathies, glaucoma and peripheral, central and ocular nervous system disorders) and type of developers (industry and non-industry). In addition, it provides details on the SARM1 inhibitors therapeutic developers, along with analyses based on their year of establishment, company size, leading players (in terms of number of SARM1 inhibitors candidates) and geographical location of the players.
  • An insightful company competitiveness analysis of SARM1 inhibitors therapeutic developers (industry and non-industry players), taking into consideration supplier strength (based on company’s experience in this field) and company competitiveness (based on phase of development, target indications and type of molecule).
  • Elaborate profiles of prominent players that are engaged in evaluating SARM1 inhibitors therapeutics, featuring a brief overview of the company, along with information on product portfolio, patent portfolio, recent developments and an informed future outlook.
  • A detailed analysis of more than 120 peer-reviewed, scientific articles related to research on SARM1 inhibitors therapeutics, over last 12 years, based on several relevant parameters, such as year of publication, type of publication, most popular journals, popular keywords, most active publishers, most popular affiliations and distribution by geography.
  • An in-depth analysis on various grants, received since the year 2014, by players engaged in this field based on year of award, support period, amount awarded, funding institute, type of grant application, activity code, type of study section, purpose of grant, prominent program officers, recipient organizations, popular NIH departments and location of recipient organizations.
  • An in-depth analysis of the various patents that have been filed / granted related to SARM1 inhibitors therapeutics, till 2022, taking into consideration several relevant parameters, such as type of patent, publication year, application year, geographical region, CPC symbols, type of applicant, key focus area, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed patent characteristics and patent valuation analysis.
  • Information on recent developments (partnerships and collaborations, and funding and investments) reported by several players engaged in the SARM1 inhibitors therapeutics domain.
  • A detailed market forecast analysis, highlighting the likely growth of the SARM1 inhibitors therapeutics in the healthcare market, over the period 2022-2040, based on several relevant parameters, such as target patient population, likely launch year of therapy candidates, approval timeline of drugs, likely price points and expected rates of adoption, across various geographical regions. The report also features the likely distribution of the current and forecasted opportunity related to SARM1 inhibitors therapeutics market across type of molecule (small molecules and biologics), target indication (multiple sclerosis, peripheral, central and ocular nervous system disorders, peripheral neuropathies, glaucoma and amyotrophic lateral sclerosis), drug developers, drug candidates and key geographical regions (North America and Europe).

Frequently Asked Questions

  • Who are the top players of SARM1 inhibitors therapeutics?
  • What is the evolving trend of publications focused on SARM1 inhibitors therapeutics?
  • How is the global intellectual property (IP) landscape of SARM1 inhibitors therapeutics likely to evolve in the foreseen future?
  • What are the recent developments and strategic initiatives undertaken by players related to research and development of SARM1 inhibitors therapeutics? 
  • What are the key factors likely to influence the evolution of SARM1 inhibitors therapeutics?
  • How is the current and future market opportunity likely to be distributed across key market segments for SARM1 inhibitors therapeutics?

Contents

Table Of Contents

1.    EXECUTIVE SUMMARY

2.    INTRODUCTION
2.1.    Overview of SARM1
2.2.    Role of SARM1 in Neurodegenerative Disorders
2.2.1.    Mechanism of Action of SARM1
2.3.    Mechanism of SARM1 Pathway Inhibition
2.4.    Future Perspectives of SARM1 inhibitors Therapeutics

3.    MARKET LANDSCAPE
3.1.    SARM1 Inhibitors: Pipeline Review
3.1.1    Analysis by Phase of Development
3.1.2.    Analysis by Type of Molecule
3.1.3.    Analysis by Phase of Development and Type of Molecule
3.1.4.    Analysis by Target Indication
3.1.5.    Analysis by Type of Developers
3.1.6.    Analysis by Phase of Development and Target Indication

3.2.    SARM1 Inhibitors: Developer Landscape
3.2.1.    Analysis by Year of Establishment
3.2.2.    Analysis by Company Size
3.2.3.    Leading Developers: Analysis by Number of Candidates
3.2.4.    Regional Landscape by Type of Player

4.    COMPANY COMPETITIVENESS ANALYSIS
4.1.    Assumptions and Key Parameters
4.2.    Methodology
4.3.    Company Competitive Analysis: Industry Players
4.4.    Company Competitive Analysis: Non-Industry Players

5.    COMPANY PROFILES
5.1.    Disarm Therapeutics
5.1.1.    Company Overview
5.1.2.    Product Portfolio
5.1.3.    Recent Patent Portfolio
5.1.4.    Recent Developments and Future Outlook

5.2.    Nura Bio
5.2.1.    Company Overview
5.2.2.    Product Portfolio
5.2.3.    Recent Patent Portfolio
5.2.4.    Recent Developments and Future Outlook

5.3.    Washington University
5.3.1.    Company Overview
5.3.2.    Product Portfolio
5.3.3.    Recent Patent Portfolio
5.3.4.    Recent Developments and Future Outlook

6.    PUBLICATION ANALYSIS
6.1.    Methodology and Parameters
6.2.    SARM1 inhibitors Therapeutics: Publication Analysis
6.2.1.    Analysis by Year of Publication
6.2.2.    Analysis by Type of Publication
6.2.3.    Most Popular Journals: Analysis by Number of Publications
6.2.4.    Most Popular Journals: Analysis by Journal Impact Factor
6.2.5.    Popular Keywords: Analysis by Key Focus Areas
6.2.6.    Most Active Publishers: Analysis by Number of Publications
6.2.7.    Most Popular Affiliations: Analysis by Number of Publications
6.2.8.    Analysis by Geography

7.    GRANT ANALYSIS
7.1.    Scope and Methodology
7.2.    Key Parameters
7.3.    SARM1 inhibitors Therapeutics: Grant Analysis

7.3.1.    Analysis by Year of Grant Awarded
7.3.2.    Analysis by Support Period
7.3.3.    Analysis by Amount Awarded
7.3.4.    Analysis by Leading Funding Institute Centre
7.3.5.    Analysis by Type of Grant
7.3.6.    Analysis by Activity Code
7.3.7.    Analysis by Study Section Involved
7.3.8.    Analysis by Purpose of Grant
7.3.9.    Prominent Program Officers: Analysis by Number of Grants
7.3.10.    Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
7.3.11.    Most Popular Departments: Analysis by Number of Grants
7.3.12.    Analysis by Location of Recipient

8.    PATENT ANALYSIS
8.1.    Scope and Methodology
8.2.    Key Parameters
8.3.    SARM1 inhibitors Therapeutics: Patent Analysis
8.3.1.    Analysis by Type of Patent
8.3.2.    Analysis by Publication Year
8.3.3.    Analysis by Application Year
8.3.4.    Analysis by Geography
8.3.5.    Analysis by CPC Symbols
8.3.6.    Analysis by Type of Applicant
8.3.7.    Analysis by Focus Area
8.3.8.    Analysis by Patent Age
8.3.9.    Leading Industry Players: Analysis by Number of Patents
8.3.10.    Leading Non-Industry Players: Analysis by Number of Patents
8.3.11.    Leading Individual Assignees: Analysis by Number of Patents
8.4.    SARM1 inhibitors Therapeutics: Patent Benchmarking Analysis
8.4.1.    Analysis by Patent Characteristics
8.5.    SARM1 inhibitors Therapeutics: Patent Valuation

9.    RECENT DEVELOPMENTS
9.1.    List of Recent Developments

10.    MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1.    Key Parameters and Assumptions
10.2.    Methodology
10.3.    SARM1 inhibitors Therapeutics: List of Forecasted Drugs
10.4    Global SARM1 inhibitors Therapeutics Market, 2033, 2037 and 2040
10.4.1.    SARM1 inhibitors Therapeutics Market: Distribution by Target Indication, 2037 and 2040
10.4.2.    SARM1 inhibitors Therapeutics Market: Distribution by Type of Molecule, 2033, 2037 and 2040
10.4.3.    SARM1 inhibitors Therapeutics Market: Distribution by Drug Developer, 2037 and 2040
10.4.4.    SARM1 inhibitors Therapeutics Market: Distribution by Drug Candidate, 2037 and 2040
10.4.5.    SARM1 inhibitors Therapeutics Market: Distribution by Geography, 2037 and 2040
10.5.    SARM1 inhibitors Therapeutics Market: Forecast of Individual Product Sales
10.5.1    DSRM-3716 (Disarm Therapeutics): Sales Forecast
10.5.2    Unnamed Molecule 1 (Disarm Therapeutics): Sales Forecast
10.5.3    Unnamed Molecule 2 (Disarm Therapeutics): Sales Forecast
10.5.4    Unnamed Molecule 3 (Disarm Therapeutics): Sales Forecast
10.5.5    Unnamed Molecule (Nura Bio): Sales Forecast
10.5.6    Unnamed Molecule (King’s College London): Sales Forecast

11.    APPENDIX 1: LIST OF FIGURES

12.    APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 1.1    Executive Summary: Overall Market Landscape
Figure 1.2    Executive Summary: Patent Analysis
Figure 1.3    Executive Summary: Publication Analysis
Figure 1.4    Executive Summary: Grant Analysis
Figure 1.5    Executive Summary: Company Competitiveness Analysis
Figure 1.6    Executive Summary: Market Sizing and Opportunity Analysis
Figure 2.1    Role of SARM1 in Neurodegenerative Disorders
Figure 2.2    Mechanism of SARM1 Pathway Inhibition
Figure 3.1    SARM1 Inhibitors: Distribution by Phase of Development
Figure 3.2    SARM1 Inhibitors: Distribution by Type of Molecule
Figure 3.3    SARM1 Inhibitors: Distribution by Phase of Development and Type of Molecule
Figure 3.4    SARM1 Inhibitors: Distribution by Target Indication
Figure 3.5    SARM1 Inhibitors: Distribution by Type of Developers
Figure 3.6    SARM1 Inhibitors: Distribution by Phase of Development and Target Indication
Figure 3.7    SARM1 Inhibitor Developers: Distribution by Year of Establishment
Figure 3.8    SARM1 Inhibitor Developers: Distribution by Company Size
Figure 3.9    Leading Developers: Distribution by Number of Candidates
Figure 3.10    Regional Landscape by Type of Player
Figure 4.1    Company Competitiveness Analysis: Industry Players
Figure 4.2    Company Competitiveness Analysis: Non-Industry Players
Figure 6.1    Publication Analysis: Distribution by Year of Publication
Figure 6.2    Publication Analysis: Distribution by Type of Publication
Figure 6.3    Most Popular Journals: Distribution by Number of Publications
Figure 6.4    Most Popular Journals: Distribution by Journal Impact Factor
Figure 6.5    Popular Keywords: Analysis by Key Focus Areas
Figure 6.6    Most Active Publishers: Distribution by Number of Publications
Figure 6.7    Most Popular Affiliations: Distribution by Number of Publications
Figure 6.8    Publication Analysis: Distribution by Geography
Figure 7.1    Grant Analysis: Distribution of Year of Grant Awarded
Figure 7.2    Grant Analysis: Distribution by Support Period
Figure 7.3    Grant Analysis: Distribution by Amount Awarded
Figure 7.4    Grant Analysis: Leading Funding Institute Center
Figure 7.5    Grant Analysis: Distribution by Type of Grant
Figure 7.6    Grant Analysis: Distribution by Activity Code
Figure 7.7    Grant Analysis: Distribution by Study Section Involved
Figure 7.8    Grant Analysis: Distribution by Purpose of Grant
Figure 7.9    Grant Analysis: Prominent Program Officers
Figure 7.10    Grant Analysis: Popular Recipient Organizations
Figure 7.11    Grant Analysis: Distribution by Popular NIH Departments
Figure 7.12    Grant Analysis: Distribution by Location of Recipient
Figure 8.1    Patent Analysis: Distribution by Type of Patent
Figure 8.2    Patent Analysis: Distribution by Publication Year
Figure 8.3    Patent Analysis: Distribution by Application Year
Figure 8.4    Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise and Country-wise)
Figure 8.5    Patent Analysis: Distribution by CPC Symbols
Figure 8.6    Patent Analysis: Distribution by Type of Applicant
Figure 8.7    Patent Analysis: Emerging Focus Area
Figure 8.8    Patent Analysis: Distribution by Patent Age
Figure 8.9    Leading Industry Players: Distribution by Number of Patents
Figure 8.10    Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.11    Leading Patent Assignees: Distribution by Number of Patents
Figure 8.12    Patent Benchmarking: Distribution by Patent Characteristics (CPC Symbols)
Figure 8.13    Patent Valuation
Figure 10.1    Global SARM1 inhibitors Therapeutics Market, 2033, 2037 and 2040 (USD Million)
Figure 10.2    SARM1 inhibitors Therapeutics Market: Distribution by Target Indication, 2037 and 2040 (USD Million)
Figure 10.3    SARM1 inhibitors Therapeutics Market: Distribution by Type of Molecule, 2033, 2037 and 2040 (USD Million)
Figure 10.4    SARM1 inhibitors Therapeutics Market: Distribution by Drug Developer, 2037 and 2040 (USD Million)
Figure 10.5    SARM1 inhibitors Therapeutics Market: Distribution by Drug Candidate, 2037 and 2040 (USD Million)
Figure 10.6    SARM1 inhibitors Therapeutics Market: Distribution by Geography, 2022 and 2040 (USD Million)
Figure 10.7    DSRM-3716 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.8    Unnamed Molecule 1 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.9    Unnamed Molecule 2 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.10    Unnamed Molecule 3 (Disarm Therapeutics): Sales Forecast, 2022-2040 (USD Million)
Figure 10.11    Unnamed Molecule (Nura Bio): Sales Forecast, 2022-2040 (USD Million)
Figure 10.12    Unnamed Molecule (King’s College London): Sales Forecast, 2022-2040 (USD Million)

List Of Tables

Table 3.1    List of SARM1 inhibitors Therapeutics Under Development
Table 3.2    List of SARM1 inhibitors Therapeutic Developers
Table 5.1    Disarm Therapeutics: Product Portfolio
Table 5.2    Disarm Therapeutics: Recent Patent Portfolio
Table 5.3    Disarm Therapeutics: Recent Developments and Future Outlook
Table 5.4    Nura Bio: Product Portfolio
Table 5.5    Nura Bio: Recent Patent Portfolio
Table 5.6    Nura Bio: Recent Developments and Future Outlook
Table 5.7    Washington University: Product Portfolio
Table 5.8    Washington University: Recent Patent Portfolio
Table 5.9    Washington University: Recent Developments and Future Outlook
Table 6.1    SARM1 inhibitors Therapeutics: List of Publications
Table 7.1    SARM1 inhibitors Therapeutics: List of Grants
Table 8.1    SARM1 inhibitors Therapeutics: List of Patents
Table 8.2    SARM1 inhibitors Therapeutics: Rank 1 IP Documents
Table 9.1    SARM1 inhibitors Therapeutics: List of Recent Developments
Table 10.1    SARM1 inhibitors Therapeutics: List of Forecasted Drugs

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. Academia Sinica
  2. Affiliated Hospital of Qingdao University (AHQU)
  3. Agilent Technologies
  4. Aichi Medical University
  5. Akershus University Hospital (Ahus)
  6. Artivila Therapeutics
  7. AstraZeneca
  8. Australian Centre for Disease Preparedness (formerly known as Australian Animal Health Laboratory)
  9. Babraham Institute
  10. Babraham Institute (a part of Babraham Research Campus)
  11. Babraham Research Campus
  12. Bar-Ilan University
  13. Ben-Gurion University of the Negev
  14. Biomedical Research Centre
  15. Boston Children’s Hospital
  16. Brandeis University
  17. Broad Institute of MIT and Harvard
  18. Case Western Reserve University School of Medicine
  19. Center for Research in Agricultural Genomics (CRAG)
  20. Center of Research in Myology (a part of Sorbonne University)
  21. Chengdu University of Traditional Chinese Medicine
  22. Children's Health Ireland (CHI)
  23. Children's Research Institute
  24. Chinese Academy of Sciences
  25. Chinese Institute for Brain Research
  26. Chonnam National University (CNU)
  27. Chungnam National University
  28. Colorado State University
  29. Columbia University
  30. Commonwealth Scientific and Industrial Research Organisation (CSIRO)
  31. Cornell University
  32. Dementia UK
  33. Disarm Therapeutics (acquired by Eli Lilly)
  34. Division of Cellular and Molecular Therapy, University of Florida
  35. Eastern Nazarene College
  36. Elysium Health®
  37. Emendo Biotherapeutics
  38. Epigenomics
  39. European Molecular Biology Laboratory (EMBL)
  40. Evotec
  41. First Affiliated Hospital, Wenzhou Medical University (WMU)
  42. Germans Trias i Pujol Research Institute (IGTP)
  43. Gladstone Institutes
  44. Griffith University
  45. Hangzhou Medical College (HMC)
  46. Hangzhou Normal University
  47. Harvard Medical School
  48. Harvard T.H. Chan School of Public Health
  49. Harvard University
  50. Hebei Research Institute for Family Planning Science and Technology
  51. Heidelberg University
  52. Heidelberg University Hospital
  53. Helmholtz Zentrum München
  54. Helmholtz Zentrum München 
  55. Hong Kong Baptist University
  56. Hope Center (a part of Washington University School of Medicine)
  57. Hôpital Lariboisière
  58. Howard Hughes Medical Institute
  59. Icahn School of Medicine at Mount Sinai
  60. INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IISER), KOLKATA
  61. Indiana University School of Medicine
  62. Inovarion
  63. Institute of Biomedical Research and Innovation (IBRI)
  64. Institute of Cancer of São Paulo (ICESP)
  65. Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences (ICG SB RAS)
  66. Institute of Molecular Biology
  67. Institute of Molecular Physiology (imP)
  68. Ionis Pharmaceuticals
  69. Jilin University
  70. Jinan Central Hospital, SDU
  71. John van Geest Centre for Brain Repair (BRC)
  72. Johns Hopkins Bloomberg School of Public Health
  73. Johns Hopkins University
  74. Johns Hopkins University School of Medicine
  75. Josep Carreras Leukaemia Research Institute (IJC)
  76. King’s College London
  77. KTH Royal Institute of Technology
  78. Massachusetts General Hospital
  79. Max Planck Institute for Biology of Ageing
  80. Max Planck Institute for Multidisciplinary Sciences
  81. Mayo Clinic
  82. McGill University
  83. Monash University
  84. MRC-University of Glasgow Centre for Virus Research
  85. National Collaborative Innovation Center for Biotherapy
  86. National Defense Medical Center
  87. National Hospital for Neurology and Neurosurgery (NHNN)
  88. National Institute of Allergy and Infectious Diseases
  89. National Institute of Health
  90. National Institute on Aging
  91. National Institutes of Health
  92. National Institutes of Health (NIH)
  93. National Research Council (NRC)
  94. National University of Singapore
  95. National University of Singapore (NUS)
  96. Needleman Center for Neurometabolism and Axonal Therapeutics
  97. Northwestern University
  98. Norwegian Centre on Healthy Ageing (No-Age)
  99. Novartis Institutes for BioMedical Research
  100. Nura Bio™
  101. NYU Long Island School of Medicine
  102. Okayama University
  103. Okayama University Graduate School of Medicine,Dentistry and Pharmaceutical Sciences
  104. Okayama University Hospital
  105. Okayama University of Science
  106. Oniris
  107. Oregon Health & Science University
  108. Oregon Health and Science University
  109. Osaka City University
  110. Oujiang Laboratory
  111. Paris-Saclay Institute of Neuroscience
  112. Peking University
  113. Peking University Shenzhen Graduate School (PKU Shenzhen)
  114. Peking University Third Hospital
  115. Powell Gene Therapy Center (PGTC), University of Florida
  116. Presidency University
  117. Qilu Hospital of Shandong University
  118. Queen's Cancer Research Institute (QCRI)
  119. Robinson Way (a subsidiary of Hoist Finance UK)
  120. Rockefeller University
  121. Royal College of Surgeons in Ireland
  122. Royal College of Surgeons of England
  123. Royal Victoria Eye and Ear Hospital
  124. Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University (WMU)
  125. Sensory Biology and Organogenesis (SBO) research unit
  126. Shandong University
  127. Shanghai General Hospital
  128. Shengjing Hospital of China Medical University
  129. Shenzhen Hong Kong Brain Science Innovation Research Institute
  130. Sichuan University
  131. South London and Maudsley NHS Foundation Trust
  132. Southern University of Science and Technology
  133. St. Jude Children's Research Hospital
  134. Stanford University
  135. Stanford University School of Medicine
  136. Sungkyunkwan University School of Medicine (SKKU-SOM)
  137. Technical University of Munich
  138. Tel Aviv University
  139. Temple University
  140. Texas Children's Hospital
  141. Tezukayama Gakuin University (TGU)
  142. The Chinese University of Hong Kong
  143. The Johns Hopkins University School of Medicine
  144. The Rockefeller university
  145. The University of Edinburgh
  146. The University of New South Wales
  147. The University of Queensland
  148. Thomas Jefferson University
  149. Trinity College Dublin
  150. Tsinghua University
  151. UCL Queen Square Institute of Neurology
  152. UCSF School of Medicine
  153. UK Dementia Research Institute
  154. UMass Chan Medical School
  155. Uniformed Services University
  156. Universidade Federal de Minas Gerais (UFMG)
  157. Universidade Federal de São Paulo
  158. Universidade Federal do Rio de Janeiro
  159. Università Politecnica delle Marche
  160. University Medical Center Göttingen
  161. University Medical Center Hamburg-Eppendorf
  162. University of Bergen
  163. University of Bordeaux
  164. University of Bristol
  165. University of California
  166. University of Cambridge
  167. University of Colorado Anschutz Medical Campus
  168. University of Dundee
  169. University of Exeter
  170. University of Freiburg
  171. University of Glasgow
  172. University of Heidelberg
  173. University of Iowa
  174. University of Lausanne
  175. University of Madras
  176. University of Manchester
  177. University of Massachusetts Amherst
  178. University of Massachusetts Medical School
  179. University of Miami
  180. University of Michigan
  181. University of New South Wales
  182. University of North Carolina
  183. University of Nottingham
  184. University of Oslo
  185. University of Ottawa
  186. University of Oxford
  187. University of Paris-Saclay
  188. University of Pennsylvania
  189. University of Queensland
  190. University of Rochester
  191. University of Rochester Medical Center
  192. University of São Paulo
  193. University of Sheffield
  194. University of South Alabama
  195. University of Texas at Austin
  196. University of Texas at San Antonio
  197. University of Texas Health Science Center
  198. University of Texas Southwestern Medical Center
  199. University of Toyama
  200. University of Tübingen
  201. University of Utah School of Medicine
  202. University of Valencia
  203. University of Virginia
  204. University of Washington
  205. University of Zurich
  206. Utrecht University
  207. Van Andel Institute
  208. Virginia Commonwealth University School of Medicine.
  209. Washington University
  210. Washington University School of Medicine
  211. Weill Cornell Medical College
  212. Weill Medical College of Cornell University
  213. Weizmann Institute of Science
  214. Wenzhou Medical University
  215. West China Hospital
  216. Yale School of Medicine
  217. Yale University
  218. Yale-NUS College
  219. Yonsei University College of Medicine
  220. Zhejiang Provincial Key Laboratory of Alzheimer's Disease Research
  221. Zhejiang Taizhou Hospital

Source 1: https://www.sciencedirect.com/science/article/pii/S2451945619303605
Source 2: https://www.nature.com/articles/s41392-020-00311-7

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.